Brief: IDEAYA Biosciences Announces Development Candidate Nomination Of IDE892
09/12/2024 11:10
Dec 9 (Reuters) - IDEAYA Biosciences Inc IDYA.O :
* IDEAYA BIOSCIENCES ANNOUNCES DEVELOPMENT CANDIDATE
NOMINATION OF
IDE892, A POTENTIAL BEST-IN-CLASS MTA-COOPERATIVE PRMT5
INHIBITOR
* IDEAYA BIOSCIENCES INC -IND-ENABLING STUDIES ONGOING AND
TARGETING IND-FILING FOR IDE892 IN MID-2025
Source text: ID:nPnbQ4HYma
Further company coverage: IDYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj